Medicenna Therapeutics Corp

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Martin Bexon - CMO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin - Bloom Burton Catherine Novack - JonesTrading Swayampakula Ramakanth - H.C. Wainwright Andre Uddin - Mackie Research Capital Shubhendu Roy - Brookline Capital Markets David Bautz - Zacks Small-Cap Research Operator Hello, and welcome to the Medicenna Therapeutics Fiscal Year-End Earnings Call.

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript

--Cash runway extended late into calendar Q2 2023

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

TORONTO and HOUSTON, June 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,352,402 titled, “Interleukin-4 Receptor-Binding Fusion Proteins And Uses Thereof.” The patent provides intellectual property (IP) protection for composition and methods of treating degenerative diseases via administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family polypeptide. The patent's term extends into at least 2038 without accounting for any potential extensions.

Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent

TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights.

Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022

-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity)

Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting

TORONTO and HOUSTON, April 27, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend the conference and present a corporate overview at the 2022 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place from May 2 – May 3, 2022.

Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

-- Anti-PD1-IL-2 BiSKIT ( Bi -functional  S uper K ines for I mmuno T herapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

-- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor

Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting

TORONTO and HOUSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of two abstracts that have been accepted for electronic poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana from April 8-13, 2022.

Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting

Medicenna's Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2

Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q3 2022 Results - Earnings Call Transcript

-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022

Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights

TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM ET to report its third quarter fiscal 2022 financial results and operational highlights.

Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022 Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022

Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

-- Peak CD8 + T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial's first two dose escalation cohorts

Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study

-- ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States

Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada

TORONTO and HOUSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna's Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an upcoming oral presentation on MDNA55. The presentation will be delivered by Dr. Sampson at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO), which is taking place November 18 – 21, 2021 at the Hynes Convention Center in Boston, Massachusetts.

Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial.

Medicenna Therapeutics: Treating Cancer With Immunomodulators

Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q2 2022 Results - Earnings Call Transcript

-- Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022

Medicenna Reports Second Quarter Fiscal 2022 Financial Results and Operational Highlights

-- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP)

Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference

Announces Results of Annual Meeting of Shareholders Announces Results of Annual Meeting of Shareholders

Medicenna Appoints Dr. John H. Sampson to its Board of Directors

TORONTO and HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that members of its leadership team will participate in the Next-Gen Cytokine Therapeutics Summit today.

Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit

-- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors

Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study

TORONTO and HOUSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the following virtual investor conferences to take place in September, 2021.

News for Medicenna Therapeutics Corp Stock (MDNA)